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INTRODUCTION
Immunosuppressive therapy has modified the early outcome of kidney transplantation, reducing the incidence of acute rejection from 30% to less than 10%. Despite this advance, long-term renal allograft survival has not mirrored the short-term improvements. Unfortunately, new approaches based on drug research, induction therapies, and immunosuppressive treatment, integrated with low-toxicity regimens, do not have a significant impact on the long-term prognosis after kidney transplantation. In the long term, renal transplantation is commonly characterized by chronic allograft dysfunction (CAD), a multifactorial pathology resulting in graft failure. A series of inflammatory events involving both cell-mediated and humoral immunity leads to progressive kidney allograft loss. CAD represents an endpoint precipitated by several biological processes that generate intolerance towards the transplanted organ, but is only partly due to involvement of major histocompatibility complex (MHC) class I antigens.
The innate immune system represents a new frontier in transplantation medicine. Innate immunity is the body's first line of defense, involving diverse mechanisms to respond to attack by foreign agents. These mechanisms include the complement system, cytokines and other soluble proteins, neutrophils, macrophages, and natural killer (NK) cells. NK cells play a special role as a bridge between innate and adaptive immunity, and thereby, critically mediate transplantation success or failure. NK cells promote both acute and chronic damage. However, recent studies have also implicated NK cells in transplant tolerance induction [1] [2] [3] .
Killer cell immunoglobulin-like receptors (KIRs) are glycoproteins expressed on the surface of NK cells and subsets of T cells. KIRs interact with specific motifs on HLA class I molecules, thus modulating NK cytotoxicity. KIRs have been divided into distinct groups, depending on the number of external immunoglobulin domains (2D or 3D). A long cytoplasmic tail containing two immune tyrosine-based inhibitory motifs (ITIMs) allows the transduction of inhibitory signals and characterizes the inhibitory KIRs (2DL, 3DL). Short cytoplasmic tails correspond to activating KIRs (2DS, 3DS).
Many studies have associated KIR genes with susceptibility to several diseases, immune responsiveness, and events following allogenic transplantation, namely haematopoietic stem cell transplantation [4] [5] [6] . A large body of evidence indicates that the risk of acute rejection in solid organ transplantation is influenced by recipient KIR and donor HLA antigen interactions. However, few studies have elucidated potential KIR system involvement in long-term transplant outcome [1, [7] [8] [9] [10] [11] [12] .
Our study evaluated the role of KIR and KIR-HLA compatibility on long-term renal function. From 2003 to 2005, we monitored kidney transplant recipients using standardized center regimens and well-established and structured transplant procedures to determine whether the KIR system per se, or KIR-HLA compatibility between recipient and donor, impacts renal function in a 5-year follow-up.
PATIENTS AND METHODS

Patients
We enrolled 113 patients who received kidney transplantation between 2003 and 2005 at our center. Exclusion criteria were cancer or other diseases with a fatal prognosis, hyperimmunization or previous transplant, renal transplantation combined with other organs (heart, liver), major urological complications, primary non function, presence of neoplasia, or acute vascular rejection.
Study design
We evaluated patient serum creatinine levels and estimated GFR (Glomerular filtration rate) at discharge, at 1 and 3 months, and at 1, 2, 3, 4, and 5 years after transplantation.
Patients whose serum creatinine levels were above the population median at 5-years post transplantation were deemed to have a deteriorated or worsened outcome. Based on these diagnostic criteria, the enrolled patient population was divided into two groups:
patients with stable renal function (SRF) and patients who experienced a worsening of renal function (WRF) at the 5-year follow-up. Patients in the two groups were comparable for sex distribution, donor and recipient age, deceased or living donor, time on dialysis, cold ischemia time, HLA mismatches, and immunosuppressive therapy schemes.
Immunosuppressive therapy
Patients received a standard immunosuppressive therapy protocol based on induction therapy with intravenous Basiliximab (20 mg on days 0 and 4), followed by steroids at decreasing dosages, and calcineurin inhibitors (cyclosporine or tacrolimus), with or without mycophenolate mofetil (MMF) or mycophenolat acid (MPA).The study protocol was approved by the Institutional Ethics Committee, and written informed consent was obtained from all subjects.
Biochemical analysis
Patient serum creatinine levels were measured at discharge, at 1 and 3 months, and at 1, 2, 3, 4, and 5 years after transplantation. Glomerular filtration rate was calculated using the 4-variable MDRD CKD EPI equation (using SI Units), a formula that takes age, sex, race, and serum creatinine level into account. Patients whose serum creatinine levels were above the population median at 5-years post transplantation were deemed to have a deteriorated or worsened outcome. 
Genotyping
Statistical analysis
We evaluated the effect of transplant recipient KIR genes and of various KIR-HLA combinations in recipient/donor pairs on serum creatinine and MDRD GFR over time, using analysis of variance (ANOVA) nonparametric repeated measures. In the presence of a significant main effect of time, a post-hoc analysis was subsequently performed using Tukey's test for evaluating differences between all possible pairs of mean creatinine values at each follow-up. Multivariate analysis of variance (MANOVA) was implemented to control for possible confounding effects of sex, hypertension, dgf, donor and recipient age, and immunosuppressive regimen. The frequencies of HLA-KIR matches were evaluated using contingency tables, and the observed values were compared with expected values using a chi-squared test or by Fisher's exact test as appropriate. Row and adjusted relative risk (RR) with 95% confidence intervals (95% CI) was also calculated using a modified Poisson regression model with robust variance estimation.
RESULTS
Specific KIR gene frequencies in our patients were consistent with those reported for the general Italian population [13] and are detailed in Table A However, renal function outcome in the coupled KIR2DS3-recipient/HLA-C1 donor scenario remained statistically significant (Table 2 ; F=3,95; p=0.0227).
To confirm these data, we evaluated these associations after dividing our patient population according to the median creatinine values at 5 years following transplantation. Sixty patients with a serum creatinine at 5 years post-transplant below the median (1.5 mg/dL at 5 years) were included in the stable renal function group (SRF), whereas 53 patients with creatinine levels above the median value were grouped as worsened renal function (WRF). Demographic, clinical, and transplant-related parameters of the patient populations are shown in Table B of the "Supplemental Digital Content 3". Table 3 compares KIR gene frequencies in SRF and WRF groups. KIR2DS3-negative recipients had an increased relative risk of 5-year creatinine levels being elevated above the median level (RR=1.453, 95% CI: 0.938-2.253), but this was not statistically significant. Additionally, compared to the KIR2DL1-negative patients, those who did not carry the KIR2DL1 gene, which is in linkage disequilibrium with KIR2DP1, showed a 2-fold higher relative risk of having a serum creatinine above the median value (RR 2.176, 95% CI: 1.779-2.663). Table 4 Some studies on hematopoietic stem cell transplantation demonstrated a correlation between the presence of KIR2DS3 in the donor DNA and the development of chronic graft-versus-host disease (GVHD) in the recipient [15, 16] . This suggests that the KIR2DS3 activating receptor on donor tissues, together with its absence in the recipient, increase the alloreactivity of donor-derived NK and T cells. However, in line with our results, previous studies reported an association between recipient KIR2DS3-positivity and a protective effect against chronic GVHD and acute myeloid leukemia, resulting in greater long-term survival [17, 18] . These associations are difficult to interpret as KIR2DS3 gene function is not completely understood. However, KIRs are clonally expressed on NK cells in a stochastic way, so that each NK cell clone expresses only a portion of its KIR genome. Thus, a substantial fraction of patient NK cells may not express KIR2DS3 even if the corresponding gene is present [19] . The specificity of these HLA ligands for the KIR3DL2 gene is well-substantiated [20] [21] [22] . A recent study showed that HLA-A11 (HLA-A*1102) also binds with high affinity to KIR2DS4. Both KIR2DS4 and KIR3DL2 share a valine-proline motif in position 71-72 [23] . Because of this structural similarity, we cannot exclude an inducing effect of HLA-A11 on NK cell cytotoxicity, by binding to the activating receptor KIR2DS4.
The role of KIR3DL2-HLA-A3/A11 interactions in vivo is still debated [20] [21] [22] 24] .
Several studies have demonstrated that during maturation, NK cells go through a process of "education" by self MHC class I molecules to become functionally competent [25] [26] [27] [28] [29] . In the absence of inhibitory KIRs, or in the presence of inhibitory KIRs but in the absence of its ligands, the cells are hyporesponsive. Fauriat et al. studied NK cell alloreactivity not only in terms of genotype, but also phenotype. Their results showed that KIR3DL2-positive NK cells were hyporesponsive even in the presence of the respective ligand HLA-A3/A11. This observation suggests that probably no peptide in the donor was present at sufficient levels to "educate" NK cells and make them functionally competent. However these authors consider the KIR3DL2-HLA-A3/A11 interaction inhibitory at the level of the target cell [30] . The results of the current study suggest that NK cells in patients who received a transplant from an HLA-A3/A11-negative donor were at a less functional maturation stage, and therefore, hyporesponsive to non-self antigens. We believe that such NK cell hyporesponsiveness was translated into the better serum creatinine concentration observed over the long term in these recipients.
Finally, we noted that KIR-ligand incompatibility with regard to the KIR3DL2-HLA-A3/A11 combination favors improved long-term serum creatinine levels. Prior studies have shown that the absence of some KIR ligands (including KIR3DL2) is associated with an anti-leukemic affect that results in a lower risk of disease recurrence and increased survival rates, after hematopoietic stem cell transplantation [5, 31, 32] .
In conclusion, this study demonstrates a likely correlation between the innate immune system and long-term kidney transplant outcome. Formerly, allogenic graft survival or failure has been almost exclusively attributed involvement off the acquired cell- 
